Artiva Biotherapeutics ARTV
NASDAQ ARTV
$11.19 +0.06 (+0.58%)
As of: Sep 4, 2026 · 3:59 PM EDT

Artiva Biotherapeutics (ARTV) Total Non-Current Liabilities (2023 - 2024)

Artiva Biotherapeutics (ARTV) posted quarterly Total Non-Current Liabilities of $22.9 million for Q4 2024, down 54.85% year-over-year from $50.6 million in Q1 2024, and down 6.77% quarter-over-quarter from $24.5 million in Q3 2024.

Analysis

Artiva Biotherapeutics (ARTV) Total Non-Current Liabilities (2023 - 2024) Analysis & Trends

Artiva Biotherapeutics (ARTV) has reported Total Non-Current Liabilities for 2 consecutive years, with $22.9 million the latest figure, recorded in Q4 2024.

  • In Q4 2024, Total Non-Current Liabilities fell 54.85% year-over-year to $22.9 million; the TTM figure through Dec 2024 stood at $22.9 million (down 54.85% YoY), while the FY2024 annual figure was $22.9 million, down 54.85% from the prior year.
  • Total Non-Current Liabilities retreated to $22.9 million in Q4 2024 per ARTV's latest filing, from $24.5 million in the prior quarter.
  • Across five years, Total Non-Current Liabilities topped out at $50.6 million in Q4 2023 and bottomed at $22.9 million in Q4 2024.
Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Total Non-Current Liabilities (Qtr)
1 Vertex Pharmaceuticals 138.47 Bn 130.62 Bn 2.84 Bn 5.92 Bn
2 Regeneron Pharmaceuticals 85.18 Bn 77.19 Bn 3.93 Bn 7.74 Bn
3 Argenx Se 63.38 Bn 58.19 Bn 1.37 Bn 40.00 Mn
4 Moderna 58.09 Bn 52.95 Bn 52.00 Mn 3.92 Bn
5 Revolution Medicines 44.33 Bn 44.33 Bn - 1.53 Bn
6 BeOne Medicines 40.02 Bn 34.92 Bn 1.53 Bn 1.88 Bn
7 Alnylam Pharmaceuticals 35.57 Bn 32.27 Bn 992.69 Mn 4.20 Bn
8 Royalty Pharma 28.45 Bn 27.61 Bn - 9.32 Bn
9 Insmed 27.48 Bn 26.32 Bn 358.27 Mn 1.17 Bn
10 Artiva Biotherapeutics 441.23 Mn 441.23 Mn - -
Historic Data

Historic Data

Download Data
DateValue
Dec 31, 2024 22.87 Mn
Sep 30, 2024 24.53 Mn
Jun 30, 2024 22.88 Mn
Dec 31, 2023 25.62 Mn